By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Retrophin, Inc. 

777 Third Avenue
22nd Floor
New York  New York  10017  U.S.A.
Phone: 646-564–3680 Fax:



Company News
Retrophin (RTRX) Reports First Quarter 2015 Financial Results 5/12/2015 11:06:27 AM
Retrophin (RTRX) Receives FDA Orphan Drug Designation For RE-024 For The Treatment Of Pantothenate Kinase-Associated Neurodegeneration 5/6/2015 10:01:19 AM
Retrophin (RTRX) Announces FDA Review Of IND For RE-024 And Clearance To Proceed With Phase 1 Clinical Study In Healthy Adult Volunteers 5/1/2015 10:45:17 AM
Retrophin (RTRX) To Report First Quarter 2015 Financial Results 4/28/2015 12:20:03 PM
Retrophin (RTRX)’s Board Of Directors Appoints John W. Kozarich, Ph.D. As Independent Director And Names Jeffrey A. Meckler As Chairman 4/1/2015 3:44:11 PM
Retrophin (RTRX) Closes Public Offering Of 7,866,000 Shares Of Common Stock And Full Exercise Of Underwriters’ Option To Purchase Additional Shares 3/25/2015 1:18:42 PM
Retrophin (RTRX) Prices Public Offering Of 6,840,000 Shares Of Common Stock 3/19/2015 12:51:08 PM
Retrophin (RTRX) Announces Proposed Public Offering Of 5,100,000 Shares Of Common Stock 3/17/2015 12:13:36 PM
Retrophin (RTRX) Reports Fourth Quarter And Full Year 2014 Financial Results 3/6/2015 7:46:34 AM
Tim Coughlin Joins Retrophin (RTRX)’s Board Of Directors 3/5/2015 11:08:07 AM